drugset
drugset / Trial / NCT05915351

Enfortumab Vedotin in Previously Treated Locally Advanced or Metastatic Pancreatic Cancer (EPIC)

NCT05915351 ↗

Phase 2 Active not recruiting 28 enrolled University of Kansas Medical Center
NaSingle-groupOpen-labelTreatment

Summary

A Phase II Open-Label Study of Enfortumab Vedotin in Patients with Previously Treated Locally Advanced, Recurrent, or Metastatic Pancreatic Adenocarcinoma (EPIC)

Timeline

Start
2023-06-30
Primary completion
2025-06-01
Completion
2026-06-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Enfortumab Vedotin Other / unclassified 1.25 mg/kg Intravenous

Indications

pancreatic ductal adenocarcinoma